Harmony Biosciences (NASDAQ: HRMY) reported Q2 EPS of $0.76, $0.15 better than the analyst estimate of $0.61. Revenue for the quarter came in at $134.2 million versus the consensus estimate of $142.02 million.

For earnings history and earnings-related data on Harmony Biosciences (HRMY) click here.